This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Astellas Pharma Gmbh. Active years: 2016-2018.
Company Filing History:
Years Active: 2016-2018
Title: Mako Ogino: Innovator in Anti-Human TSLP Receptor Antibodies
Introduction
Mako Ogino is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target the human TSLP receptor. With a total of 2 patents to her name, her work has the potential to impact the treatment of asthma and allergic reactions.
Latest Patents
Mako Ogino's latest patents include an innovative anti-human TSLP receptor antibody. This antibody specifically binds to the human TSLP receptor and inhibits its action. The invention outlines a method for preventing or treating asthma by administering this antibody or an antigen-binding fragment thereof. The research revealed that the anti-human TSLP receptor antibody inhibits the expression of TARC mRNA induced by TSLP and the production of MDC proteins. Furthermore, it has been shown to suppress allergic reactions in a monkey antigen sensitization model.
Career Highlights
Mako Ogino is currently associated with Astellas Pharma GmbH, where she continues her research and development efforts. Her work has been instrumental in advancing therapeutic options for patients suffering from asthma and other allergic conditions.
Collaborations
Mako has collaborated with notable colleagues, including Hiromu Sato and Daisuke Yamajuku. These partnerships have fostered a collaborative environment that enhances the innovation process.
Conclusion
Mako Ogino's contributions to the field of biotechnology, particularly through her patents on anti-human TSLP receptor antibodies, highlight her role as a key innovator. Her work not only advances scientific understanding but also holds promise for improving patient care in asthma treatment.